MaxCyte (MXCT) Competitors

MaxCyte logo
$1.18 -0.01 (-0.42%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MXCT vs. SLP, NAUT, LAB, QSI, and QTRX

Should you buy MaxCyte stock or one of its competitors? MaxCyte's main competitors and comparable companies include Simulations Plus (SLP), Nautilus Biotechnology (NAUT), Standard BioTools (LAB), Quantum-Si (QSI), and Quanterix (QTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does MaxCyte compare to Simulations Plus?

MaxCyte (NASDAQ:MXCT) and Simulations Plus (NASDAQ:SLP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Simulations Plus has a net margin of 9.88% compared to MaxCyte's net margin of -81.40%. Simulations Plus' return on equity of 13.50% beat MaxCyte's return on equity.

Company Net Margins Return on Equity Return on Assets
MaxCyte-81.40% -15.05% -12.79%
Simulations Plus 9.88%13.50%12.45%

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 78.1% of Simulations Plus shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by company insiders. Comparatively, 19.1% of Simulations Plus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, MaxCyte had 2 more articles in the media than Simulations Plus. MarketBeat recorded 3 mentions for MaxCyte and 1 mentions for Simulations Plus. MaxCyte's average media sentiment score of 0.68 beat Simulations Plus' score of 0.00 indicating that MaxCyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MaxCyte
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Simulations Plus
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MaxCyte has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Simulations Plus has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

MaxCyte presently has a consensus target price of $4.50, suggesting a potential upside of 273.44%. Simulations Plus has a consensus target price of $17.25, suggesting a potential downside of 6.76%. Given MaxCyte's stronger consensus rating and higher possible upside, equities analysts plainly believe MaxCyte is more favorable than Simulations Plus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MaxCyte
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Simulations Plus
1 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.83

MaxCyte has higher earnings, but lower revenue than Simulations Plus. MaxCyte is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MaxCyte$33.03M3.77-$44.63M-$0.26N/A
Simulations Plus$82.06M4.56-$64.72M$0.4046.25

Summary

Simulations Plus beats MaxCyte on 9 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Nautilus Biotechnology?

MaxCyte (NASDAQ:MXCT) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

MaxCyte has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Nautilus Biotechnology has a net margin of 0.00% compared to MaxCyte's net margin of -81.40%. MaxCyte's return on equity of -15.05% beat Nautilus Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
MaxCyte-81.40% -15.05% -12.79%
Nautilus Biotechnology N/A -42.68%-34.39%

In the previous week, MaxCyte and MaxCyte both had 3 articles in the media. Nautilus Biotechnology's average media sentiment score of 1.82 beat MaxCyte's score of 0.68 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MaxCyte
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nautilus Biotechnology
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

MaxCyte presently has a consensus target price of $4.50, suggesting a potential upside of 273.44%. Nautilus Biotechnology has a consensus target price of $3.83, suggesting a potential upside of 62.09%. Given MaxCyte's higher possible upside, equities analysts plainly believe MaxCyte is more favorable than Nautilus Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MaxCyte
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Nautilus Biotechnology
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60

MaxCyte has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MaxCyte$33.03M3.77-$44.63M-$0.26N/A
Nautilus BiotechnologyN/AN/A-$59M-$0.46N/A

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

MaxCyte beats Nautilus Biotechnology on 9 of the 15 factors compared between the two stocks.

How does MaxCyte compare to Standard BioTools?

Standard BioTools (NASDAQ:LAB) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

MaxCyte has a consensus target price of $4.50, suggesting a potential upside of 273.44%. Given MaxCyte's stronger consensus rating and higher probable upside, analysts plainly believe MaxCyte is more favorable than Standard BioTools.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Standard BioTools
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
MaxCyte
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 26.8% of Standard BioTools shares are held by insiders. Comparatively, 4.1% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Standard BioTools has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Standard BioTools has a net margin of 157.62% compared to MaxCyte's net margin of -81.40%. Standard BioTools' return on equity of -5.61% beat MaxCyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Standard BioTools157.62% -5.61% -4.73%
MaxCyte -81.40%-15.05%-12.79%

In the previous week, MaxCyte had 2 more articles in the media than Standard BioTools. MarketBeat recorded 3 mentions for MaxCyte and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.46 beat MaxCyte's score of 0.68 indicating that Standard BioTools is being referred to more favorably in the media.

Company Overall Sentiment
Standard BioTools Positive
MaxCyte Positive

MaxCyte has lower revenue, but higher earnings than Standard BioTools. MaxCyte is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Standard BioTools$85.33M2.85-$74.90M$0.222.80
MaxCyte$33.03M3.77-$44.63M-$0.26N/A

Summary

Standard BioTools beats MaxCyte on 9 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Quantum-Si?

Quantum-Si (NASDAQ:QSI) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

In the previous week, Quantum-Si had 6 more articles in the media than MaxCyte. MarketBeat recorded 9 mentions for Quantum-Si and 3 mentions for MaxCyte. Quantum-Si's average media sentiment score of 1.04 beat MaxCyte's score of 0.68 indicating that Quantum-Si is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Quantum-Si
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MaxCyte
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

MaxCyte has a net margin of -81.40% compared to Quantum-Si's net margin of -6,729.80%. MaxCyte's return on equity of -15.05% beat Quantum-Si's return on equity.

Company Net Margins Return on Equity Return on Assets
Quantum-Si-6,729.80% -44.72% -41.26%
MaxCyte -81.40%-15.05%-12.79%

Quantum-Si presently has a consensus price target of $2.50, indicating a potential upside of 143.90%. MaxCyte has a consensus price target of $4.50, indicating a potential upside of 273.44%. Given MaxCyte's higher possible upside, analysts clearly believe MaxCyte is more favorable than Quantum-Si.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quantum-Si
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
MaxCyte
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

39.9% of Quantum-Si shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 22.0% of Quantum-Si shares are held by insiders. Comparatively, 4.1% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Quantum-Si has a beta of 3.26, indicating that its stock price is 226% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

MaxCyte has higher revenue and earnings than Quantum-Si. MaxCyte is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quantum-Si$2.44M91.95-$101.34M-$0.39N/A
MaxCyte$33.03M3.77-$44.63M-$0.26N/A

Summary

Quantum-Si and MaxCyte tied by winning 8 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Quanterix?

MaxCyte (NASDAQ:MXCT) and Quanterix (NASDAQ:QTRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by insiders. Comparatively, 1.5% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MaxCyte has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Quanterix has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

In the previous week, Quanterix had 2 more articles in the media than MaxCyte. MarketBeat recorded 5 mentions for Quanterix and 3 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.68 beat Quanterix's score of -0.03 indicating that MaxCyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MaxCyte
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Quanterix
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

MaxCyte currently has a consensus target price of $4.50, indicating a potential upside of 273.44%. Quanterix has a consensus target price of $3.50, indicating a potential upside of 20.90%. Given MaxCyte's stronger consensus rating and higher probable upside, research analysts clearly believe MaxCyte is more favorable than Quanterix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MaxCyte
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Quanterix
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

MaxCyte has higher earnings, but lower revenue than Quanterix. MaxCyte is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MaxCyte$33.03M3.77-$44.63M-$0.26N/A
Quanterix$147.91M0.93-$107.15M-$2.36N/A

Quanterix has a net margin of -75.05% compared to MaxCyte's net margin of -81.40%. MaxCyte's return on equity of -15.05% beat Quanterix's return on equity.

Company Net Margins Return on Equity Return on Assets
MaxCyte-81.40% -15.05% -12.79%
Quanterix -75.05%-30.49%-22.44%

Summary

MaxCyte beats Quanterix on 11 of the 16 factors compared between the two stocks.

Get MaxCyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MXCT vs. The Competition

MetricMaxCyteLife Sciences Tools & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$121.32M$10.75B$7.74B$11.62B
Dividend YieldN/A1.45%2.46%4.43%
P/E Ratio-4.5251.1234.1629.83
Price / Sales3.678.348.485.62
Price / CashN/A26.6921.9322.50
Price / Book0.804.454.373.66
Net Income-$44.63M$57.48B$3.52B$392.18M
7 Day Performance3.98%-4.85%-5.43%-4.26%
1 Month Performance-9.62%-1.00%-4.54%-6.73%
1 Year Performance-27.91%20.94%-1.42%-7.08%

MaxCyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MXCT
MaxCyte
3.564 of 5 stars
$1.18
-0.4%
$4.50
+283.0%
-25.3%$121.32M$33.03MN/A91
SLP
Simulations Plus
0.1902 of 5 stars
$18.50
flat
$17.25
-6.8%
N/A$374.16M$82.06M46.25160
NAUT
Nautilus Biotechnology
3.0724 of 5 stars
$2.33
-2.3%
$3.83
+64.9%
+16.7%$296.14MN/AN/A130
LAB
Standard BioTools
2.6826 of 5 stars
$0.71
+8.5%
N/A-49.9%$279.12M$85.33M3.21389
QSI
Quantum-Si
3.5199 of 5 stars
$1.16
-5.3%
$2.50
+116.5%
-22.6%$252.81M$2.44MN/A145

Related Companies and Tools


This page (NASDAQ:MXCT) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners